Format

Send to

Choose Destination
BJOG. 2019 Feb 16. doi: 10.1111/1471-0528.15657. [Epub ahead of print]

A commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm.

Author information

1
Barts Cancer Institute, Queen Mary University of London, Old Anatomy Building, Charterhouse Square, London, EC1M 6BQ, UK.
2
Department of Gynaecological Oncology, St Bartholomew's Hospital, London, UK, EC1A 7BE.
3
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, UK.

Abstract

BRCA1/BRCA2 genes were discovered in early 1990s and clinical testing for these has been available since the mid-1990s. National Institute of Health and Care Excellence (NICE) and other international guidelines recommend genetic-testing at a ~10% probability threshold of carrying a BRCA-mutation. A detailed three generation family-history (FH) of cancer is used within complex mathematical models (e.g. BOADICEA, BRCAPRO, Manchester-Scoring-System) or through standardized clinical-criteria to identify individuals who fulfil this probability threshold and can be offered genetic-testing. Identification of unaffected carriers is important given the high risk of cancer in these women and the effective options available for clinical management which can reduce cancer risk, improve outcomes and minimise burden of disease. This article is protected by copyright. All rights reserved.

PMID:
30770625
DOI:
10.1111/1471-0528.15657

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center